Frovatriptan

Clinical data
Trade names	Frova
Other names	6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide (6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
AHFS/Drugs.com	Monograph
MedlinePlus	a604013
Pregnancy category	AU: B3
Routes of administration	Oral
ATC code	N02CC07 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	20–30%
Metabolism	Hepatic
Elimination half-life	26 hours
Excretion	Renal
Identifiers
IUPAC name (+)-(R)-3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
CAS Number	158747-02-5 Y succinate: 158930-17-7 Y
PubChem CID	77992
IUPHAR/BPS	7191
DrugBank	DB00998 Y
ChemSpider	70378 Y
UNII	H82Q2D5WA7 succinate: D28J6W18HY Y
KEGG	D07997 N
ChEMBL	ChEMBL1279 Y
CompTox Dashboard (EPA)	DTXSID0023080
Chemical and physical data
Formula	C14H17N3O
Molar mass	243.310 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN[C@@H]3CCc2[nH]c1ccc(C(N)=O)cc1c2C3
InChI InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 Y Key:XPSQPHWEGNHMSK-SECBINFHSA-N Y
NY (what is this?)  (verify)

Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches^[1] and for short term prevention of menstrual migraine.^[2] The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.^[3]

Medical uses

Frovatriptan is used in the treatment of migraine.

Available forms

It is available as 2.5 mg tablets.

Contraindications

Frovatriptan should not be given to patients with:

• Ischemic heart disease
• Cerebrovascular syndrome
• Peripheral vascular disease
• Uncontrolled hypertension
• Hemiplegic or basilar migraine

Side effects

Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Pharmacology

Pharmacodynamics

Frovatriptan is a serotonin receptor agonist, with high affinity for the 5-HT_1B/1D receptors. It has no significant effects on the GABA_A mediated channel activity and benzodiazepine binding sites. Frovatriptan inhibits excessive dilation of arteries that supply blood to the head.

Pharmacokinetics

Frovatriptan has a terminal elimination half-life of approximately 26 hours, making it the longest within its class.^[4]

Society and culture

US licensing

Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006.^[5]